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The high-mobility group AT-hook 1 (HMGA1) protein is a nuclear architectural factor that
can organize chromatin structures. It regulates gene expression by controlling the for-
mation of stereospecific multiprotein complexes called “enhanceosomes” on the AT-rich
regions of target gene promoters. Previously, we reported that defects in HMGA1 caused
decreased insulin receptor expression and increased susceptibility to type 2 diabetes mel-
litus in humans and mice. Interestingly, mice with disrupted HMGA1 gene had significantly
smaller islets and decreased insulin content in their pancreata, suggesting that HMGA1
may have a direct role in insulin transcription and secretion. Herein, we investigate the regu-
latory roles of HMGA1 in insulin transcription. We provide evidence that HMGA1 physically
interacts with PDX-1 and MafA, two critical transcription factors for insulin gene expression
and beta-cell function, both in vitro and in vivo. We then show that the overexpression of
HMGA1 significantly improves the transactivating activity of PDX-1 and MafA on human and
mouse insulin promoters, while HMGA1 knockdown considerably decreased this transac-
tivating activity. Lastly, we demonstrate that high glucose stimulus significantly increases
the binding of HMGA1 to the insulin (INS) gene promoter, suggesting that HMGA1 may
act as a glucose-sensitive element controlling the transcription of the INS gene. Together,
our findings provide evidence that HMGA1, by regulating PDX-1- and MafA-induced trans-
activation of the INS gene promoter, plays a critical role in pancreatic beta-cell function and
insulin production.
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INTRODUCTION
Production and secretion of insulin from beta cells of the pancreas
maintain glucose homeostasis in vertebrates (from fish to human).
Absence or dysfunction of beta cells results in diabetes mellitus, a
set of genetically heterogeneous disorders featured by high blood
sugar and related complications. The majority of diabetes is type 2
diabetes, which is featured by defects in both pancreatic insulin
secretion (beta-cell dysfunction) and peripheral insulin action
(insulin resistance) (1, 2). Therefore, understanding beta-cell gen-
eration and insulin production/secretion holds keys to understand
and potentially cure diabetes.
Insulin production in beta cells is controlled at both tran-
scriptional and translational levels (3). High glucose upregulates
both insulin transcription and preproinsulin translation. To this
end, glucose regulates proinsulin translation by altering the phos-
phorylation status of eukaryotic initiation factor 2α (4), while it
promotes insulin transcription by activation of several beta-cell
specific transcription factors (5). Yet, direct connections between
high glucose and activation of beta-cell transcription factors have
not been established.
Regulation of insulin (INS) gene expression has been charac-
terized by several groups. A 500-bp stretch of DNA upstream of
the INS transcription start site controls its transcription. Several
cis-acting regulatory sequences reside in this region, with highly
conserved A3, C1, E1, and CRE cis-acting regulatory elements (6,
7). These promoter regions bind ubiquitous factors and a pool of
beta-cell specific transcription factors (8–14). Among these, the
pancreatic and duodenal homeobox factor-1 (PDX-1) and MafA
(V-maf musculoaponeurotic fibrosarcoma oncogene homolog A)
are the most notable factors. PDX-1 forms multiprotein complexes
with several beta-cell transcription factors to synergistically acti-
vate the INS promoter (7). It also mediates a role of high glucose
in the up-regulation of INS transcription in humans and rodents
(15–22). Consequently, targeted disruption of PDX-1 gene in beta
cells leads to beta-cell dysfunction and overt diabetes in mice (23),
whereas mutations in PDX-1 have been linked to pancreatic age-
nesis and diabetes in humans (24, 25). Similarly, MafA activates
INS transcription through the E1 and C1 elements of the INS gene
promoter (26–31). Its inactivation results in immature beta cells
with lowered insulin expression and secretion and severe glucose
intolerance (32, 33).
High-mobility group AT-hook 1 (HMGA1) is an architectural
transcription factor that binds to the minor groove of AT-rich
regions of DNA (34). This binding alters the DNA conformation
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and recruits transcription factors to the transcription initiation
site to assemble stereospecific DNA–protein complexes (so-called
enhanceosomes) that drive gene transcription (35, 36). The fact
that HMGA1 is expressed at high levels in most cell types dur-
ing embryonic development suggests its wide-spread roles in gene
expression and function (37). We have previously demonstrated
that loss of function in HMGA1 in both human and mice com-
promised pancreatic endocrine function and resulted in diabetes
(38). We further showed that binding of PDX-1 to the INS gene
promoter was reduced in nuclear extracts from HMGA1-deficient
mice, in which PDX-1 protein expression was unaffected com-
pared with wild-type animals (38). Furthermore, perturbation of
HMGA1 in the insulin-secreting beta-cell line INS-1 transfected
with an antisense expression vector specific for HMGA1 impaired
glucose-stimulated insulin secretion, suggesting that HMGA1 may
have a direct role in insulin production and pancreatic islet devel-
opment through PDX-1 and/or other nuclear molecular partners.
In this context, it is noteworthy that Ins gene transcription is
reduced in Hmga1-deficient mice, in which pancreatic islets are
up to 80% smaller compared to those of wild-type mice (38), and
reports of others have suggested that HMGA1 binds to the A3/4
region of the INS gene promoter (14).
In this study, we investigated whether HMGA1 can directly
activate the INS gene by synergizing with PDX-1 and MafA. Addi-
tionally, the effect of glucose on HMGA1 affinity to the INS gene
promoter was also investigated.
MATERIALS AND METHODS
GLUTATHIONE S-TRANSFERASE PULL-DOWN ASSAY AND
CO-IMMUNOPRECIPITATION
Human 35S-labeled PDX-1 and MafA proteins were synthesized
in vitro using the TNT-T7 quick-coupled transcription/translation
system (Promega), as previously reported (36). Glutathione S-
transferase (GST)-tagged human HMGA1 was obtained using
the pcDNA1-GST/HMGA1 expression vector, a kind gift from D.
Thanos (Biomedical Research Foundation, Academy of Athens,
Athens, Greece). For direct coupling of antibody to protein A-
Sepharose beads (GE Healthcare), an anti-HMGA1 polyclonal
antibody was mixed with beads and bound for 1 h with rotation
at room temperature, as described previously (36). Antibody-
coupled protein A beads were washed twice in phosphate-buffered
saline and used in immunoprecipitation studies. Briefly, aliquots
of INS-1 cell nuclear extract, HMGA1, PDX-1, or MafA together
were incubated for 3 h with rotation at 4°C with 10µl of antibody-
coupled protein A beads. Beads were recovered by gentle centrifu-
gation and washed three times with 500µl of NETN wash buffer
[0.1% NP-40, 150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl (pH
8.0)]. Protein was removed from the beads by boiling in sample
buffer for 5 min and analyzed by SDS-PAGE and immunoblot-
ting (39). Antibodies used for these studies were as follows:
anti-HMGA1 (39), anti-PDX-1 (40), and anti-MafA (Abcam).
CELL CULTURES AND NUCLEAR EXTRACTS
Human embryonic kidney (HEK) 293 cells and human epithe-
lial carcinoma (HeLa) cells were cultured in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum (FBS), 2 mM gluta-
mine, penicillin (100 U/ml), and streptomycin (100µg/ml) in a
humidified 5% CO2 atmosphere at 37°C. INS-1 rat insulinoma
cells were cultured in RPMI-1640 medium supplemented with
10% FBS, 2 mM glutamine, penicillin (100 U/ml), streptomycin
(100µg/ml), 50µM beta-mercaptoethanol, and 100 mM HEPES
buffer (Sigma). Nuclear extracts were prepared from cultured cells
as described previously (41, 42). For each extract, an equal number
of nuclei were homogenized, and the final protein concentration
in the extracts was determined using the colorimetric assay of
Bradford (Bio-Rad).
PLASMID VECTORS, SMALL INTERFERING RNA, AND TRANSIENT
TRANSFECTION
The promoter regions of human and mouse INS genes were
amplified from genomic DNA, using modified specific primers
(Table 1). Sequence-verified promoters were then cloned into
the pGL3-basic reporter vector (Promega) to generate the human
(phINS-Luc) and mouse (pmINSII-Luc) luciferase (Luc) reporter
plasmids. The expression plasmids were as follows: pcDNA3/HA-
HMGA1 (a generous gift from G. Manfioletti, University of Tri-
este, Italy); pcDNA3-MafA (a generous gift from P. Gold, Gold
Biotechnology, Inc., St. Louis, MO, USA); pSG5-ATG-hPDX-1
(a generous gift from C. V. Wright, Vanderbilt University Med-
ical Center, Nashville, TN, USA). For gene silencing experiments,
mouse and human anti-HMGA1 small interfering RNAs (siRNAs)
(Santa Cruz Biotech) were used. In all knockdown experiments,
cells were transfected with 100 pmol of HMGA1 siRNA in 6 well
plates, and incubated without further treatment for 72 h before
being used in subsequent analyses. Transient transfections of cul-
tured cells were carried out using the Lipofectamine 2000 method
(Invitrogen), and Luc activity was assayed 48–96 h later, using the
dual-luciferase reporter assay system (Promega) (43).
GLUCOSE STIMULATION OF INSULIN RELEASE
INS-1 cells (ATCC) were cultured in RPMI-1640 medium
(GIBCO) supplemented with 10% FBS, 2 mM glutamine,
penicillin (100 U/ml), streptomycin (100µg/ml), 50µM beta-
mercaptoethanol, 100 mM HEPES, in a humidified 5% CO2
atmosphere at 37°C. For insulin secretion, INS-1 cells were
transiently transfected at 60% confluence with HMGA1 siRNA
or negative control siRNA as above. Seventy-two hours later
Table 1 | Primers used for plasmid construction of human and mouse
INS promoter-containing vectors.
Name Sequence (5′–3′) Positiona Restriction
site
Human
INS for
accaccttggtacctccatggcggcatctt −810/−781 KpnI
Human
INS rev
tgtgtagaagaagcttcgttccccg +366/+390 HindIII
Mouse
InsII for
agaaaggtttggtacctggaatagagc −683/−653 KpnI
Mouse
InsII rev
gtagaagaagcttcgctccccaca +301/+324 HindIII
aFrom the transcription start site. Modified bases are underlined.
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the tissue culture medium was switched to fresh medium con-
taining 5 mmol/l glucose and the cells were grown for addi-
tional 18 h. After this, the cells were washed with Hanks’ bal-
anced salt solution (HBSS) containing 140 mM NaCl, 4.7 mM
KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM HEPES, 2.5 mM
CaCl2, 25.5 mM NaHCO3, 0.2% BSA, and further incubated for
2 h in either low (3 mM) or high (15 mM) glucose condition.
Then, the insulin concentration in the medium was measured by
a commercial rat insulin ELISA kit (Mercodia Inc.).
CHROMATIN IMMUNOPRECIPITATION
Chromatin immunoprecipitation (ChIP) was performed in INS-1
cells as described previously (38). As soon as the cells reached con-
fluence, they were incubated in HBSS buffer with 3 or 15 mM glu-
cose for 30 min at 37°C. Then, the cells were washed with 1× PBS
and fresh RPMI was added. DNA–protein complexes were cross-
linked by adding formaldehyde diluted to 1% final concentration
for 10 min at room temperature, followed by blocking with glycine
for 2 min. Cells were washed twice with cold PBS and lysed on ice
using SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8).
Chromatin samples were sonicated on ice and the formaldehyde-
fixed DNA–protein complexes were immunoprecipitated with
anti-HMGA1 antibody (Santa Cruz Biotech) and the following
sequence-specific primers for the rat InsI gene promoter were
used for PCR amplification of immunoprecipitated DNA, using
PCR ready-to-go beads (GE Healthcare). Rat InsI (NC_005100.3):
for 5′-CTGGGAAATGAGGTGGAAAA-3′ (−328/−308 from the
trasncription start site); rev 5′-AGGAGGGGTAGGTAGGCAGA-
3′ (−108/−88 from the trasncription start site). PCR products
were electrophoretically resolved on 1.5% agarose gel and stained
with ethidium bromide staining solution. PCR products were
confirmed by sequence analysis.
REAL-TIME PCR
For qRT-PCR, total cellular RNA was extracted from INS-1 cells
using the RNAqueous-4PCR kit and subjected to DNase treatment
(Ambion). RNA levels were normalized against 18S ribosomal
RNA in each sample, and cDNAs were synthesized from 2µg
of total RNA using the RETROscript first strand synthesis kit
(Ambion). Primers for rat InsI, HMGA1, PDX-1, MafA, and Rps9
were designed according to sequences from the GenBank database
(Table 2). A real-time thermocycler (Eppendorf Mastercycler ep
realplex ES) was used to perform quantitative PCR. SYBR Green
fluorescence was measured, and relative quantification was made
against the Rps9 cDNA used as an internal standard (44). All PCR
reactions were done in triplicate.
STATISTICAL ANALYSIS
All calculations were performed with SPSS 20.0 statistical software
(SPSS Inc.). Mean values were compared with t -tests. A p-value
<0.05 (two-tailed) was considered significant.
RESULTS
HMGA1 PHYSICALLY INTERACTSWITH PDX-1 ANDMafA IN VITRO AND
IN VIVO
Figure 1 shows a schematic representation of the promoter region
of human, mouse, and rat INS genes. Binding sites for HMGA1,
Table 2 | Gene-specific primers for Real-Time PCR.
Name Sequence (5′–3′) Size (bp) Accession no.
Rat RPS9 for tttgtcgcaaaacctatgtgacc 175 NM_031108.3
Rat RPS9 rev ttctcgtccagcgtcaacag
Rat HMGA1 for aaagttaccacaactccggg 173 XM_006256160.1
Rat HMGA1 rev agcagggcttccagtcccag
Rat PDX-1 for aaatccaccaaagctcacgc 188 NM_022852.3
Rat PDX-1 rev aagttgagcatcactgccagc
Rat MafA for aggaggaggtcatccgactg 113 XM_006241903.1
Rat MafA rev cttctcgctctccagaatgtg
Rat InsI for gacccgcaagtgccacaa 101 NM_019129
Rat InsI rev tccacaagccacgcttctg
PDX-1, and MafA were identified within the promoter of the rat
Ins gene by sequence analysis with MatINspector (version 8.1,
Genomatix, http://www.genomatix.de/). Bioinformatics analysis
of the human and mouse INS promoters predicted no HMGA1
binding sites, although the existence of non-recognizable DNA
motifs cannot be completely excluded. Instead, binding sites for
PDX-1 and MafA were predicted in these promoters as for the
rat Ins gene. Consistent with this DNA promoter analysis, the
existence of HMGA1 in a cocomplex with PDX-1 was demon-
strated previously by us and others in supershift experiments
in electrophoretic mobility shift assays using anti-HMGA1 and
anti-PDX-1 antibodies, in the presence of the rat InsI E2A3/4
mini-enhancer DNA (14, 38). In both investigations, binding of
PDX-1 to this promoter element was increased in the presence of
HMGA1, suggesting a functional cooperation between HMGA1
and PDX-1 on the INS promoter.
In an attempt to determine whether and/or how HMGA1 reg-
ulates INS gene expression, we first analyzed whether HMGA1
interacts with PDX-1 and MafA without DNA. In vitro-translated
35S-labeled proteins PDX-1 and MafA were analyzed for their abil-
ity to be specifically retained by a GST-HMGA1 affinity resin. As
shown in Figure 2A, PDX-1 and MafA were both retained by
GST-HMGA1, but not GST alone, indicating that both these fac-
tors physically interact with HMGA1 in vitro, in the absence of
DNA. The high specificity of the interaction of HMGA1 with
PDX-1 and MafA was highlighted by the observation that no
protein–protein contact was detected between HMGA1 and Neuro
D (Figure 2A), a transactivator that is critical for INS gene expres-
sion in both human and mouse beta cells (45). To verify whether
this protein–protein interaction in vitro could occur also in vivo,
we performed co-immunoprecipitation studies using an anti-
HMGA1 antibody immobilized on protein A-Sepaharose beads.
As shown in Figure 2B, immunoprecipitation of HMGA1 from
INS-1 nuclear extracts specifically pulled down PDX-1 and MafA,
as shown by Western Blot analysis with well-characterized anti-
PDX-1 or anti-MafA antibodies. These findings unequivocally
demonstrate that HMGA1 physically interacts with PDX-1 and
MafA both in vitro and in vivo, and suggest that physical interac-
tions between these nuclear factors may constitute a fundamental
prerequisite for functional cooperation between HMGA1, PDX-1,
and MafA.
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FIGURE 1 | Schematic representation of the human (INS), rat (InsI ), and mouse (InsII ) promoter regions. HMGA1, PDX-1, and MafA binding sites are
underlined in each gene sequence. The numbers indicate positions in base pairs relative to the transcriptional start site (+1). The rat insulin mini-enhancer
element E2A3/4 is indicated.
HMGA1 POTENTIATES THE ACTIVITIES OF PDX-1 AND MafA ON INS
GENE TRANSCRIPTION
We next determined whether HMGA1, PDX-1, and MafA func-
tionally cooperate to activate INS transcription. HEK-293 cells
were cotransfected transiently with Luc reporter plasmids con-
taining human or mouse INS gene promoter and various effector
vectors. HEK-293 cells were ideally suited for studying the effects
of these proteins on transcription since they express only low lev-
els of HMGA1 and no PDX-1 or MafA. As shown in Figure 3A,
forced expression of single transcription factors HMGA1, PDX-1,
and MafA in HEK-293 cells activated the human INS promoter to
levels of two to threefold above the background with the recom-
binant reporter vector (phINS-Luc) alone. An ulterior increase
in promoter activity was found in the presence of a combina-
tion of two of these transcription factors, while a further additive
effect was observed in the promoter activity of phINS-Luc in cells
overexpressing all three proteins (HMGA1, PDX-1, and MafA)
together. Comparable or better results were obtained in HEK-293
cells when the mouse Ins promoter (pmInsII-Luc) was utilized for
transactivation assays (Figure 3B). Differences in the activity of
human and mouse INS gene promoters in HEK-293 cells may
reflect the differences between humans and mice in terms of tran-
scriptional activation of genes associated with pancreatic function
(38). The greater increase in promoter activity of the pmInsII-Luc
compared to the phINS-Luc in cells overexpressing MafA is likely
attributable to the greater number of MafA binding sites within
the mouse InsII promoter. Given that full sequence analysis with
MatINspector predicted no HMGA1 binding sites in the human
and mouse INS promoters, these results indicate that HMGA1
acts in concert with PDX-1 and MafA to regulate the expression
of human and mouse INS genes through a mechanism that does
not require its direct binding to DNA. Similar findings, indicating
that HMGA1 acts to regulate the expression of estrogen responsive
genes through a mechanism that does not require direct binding
to DNA, have been reported elsewhere (46).
We next tested whether HMGA1 is required for high transacti-
vation activity of PDX-1 and MafA on INS gene in beta cells. For
this purpose, we performed HMGA1 knockdown in INS-1 cells
with siRNA approaches. As shown in Figure 4A, INS-luc activity
failed to increase in INS-1 cells with overexpression of HMGA1,
PDX-1, and MafA separately or in combination, probably because
of the saturating levels of endogenous HMGA1, PDX-1, and MafA
in this insulin-producing cell line. However, the promoter activ-
ity of pmInsII-Luc was significantly blunted in INS-1 cells with
HMGA1 knockdown (Figure 4A), indicating that HMGA1 is
required for full activation of INS transcription in vivo. A sim-
ilar reduction in INS promoter activity was observed in HeLa cells
that naturally express HMGA1 but not PDX-1 and MafA. In this
case, whereas ectopic expression of PDX-1 and MafA, together,
only weakly activated the expression of the reporter vector phINS-
Luc, knockdown of endogenous HMGA1 significantly prevented
this activation (Figure 4B). Consistently with the results reported
above, and in agreement with our previous findings that pancre-
atic insulin mRNA transcripts were reduced in HMGA1-knockout
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FIGURE 2 | Physical association between HMGA1, PDX-1, and MafA.
(A) SDS-PAGE of 35S-PDX-1, 35S-MafA, and 35S-NeuroD bound to GST or
GST-HMGA1 resin (lanes 1–9). In lanes 1, 4, and 7 labeled protein was added
directly onto the gel without binding to and elution from GST protein resin.
(B) Immunoprecipitation (IP) of HMGA1, PDX-1, and MafA by using the
anti-HMGA1 antibody followed by immunoblotting with the anti-PDX-1
antibody (lanes 1–3), the anti-MafA antibody (lanes 4–6), or the anti-HMGA1
antibody (lanes 7–9) after reprobing the same transfer. Lanes: 1, 4, and 7,
10 ng of pure HMGA1, 2, 5, and 8, INS-1 nuclear extract (NE; 500µg). In lanes
1, 4, and 7, protein was directly applied to the gel without binding to and
elution from protein A beads. To prove specificity, pure Sp1 (15 ng) was used
for immunoprecipitation by the anti-HMGA1 antibody (lanes 3, 6, and 9,
control). The faint band in lane 8 at 43 kDa represents non-specific signal. A
representative of three separate assays is shown for each condition.
mice (38), INS mRNA levels were significantly lower in INS-1
cells in the presence of siRNA directed against HMGA1, whereas
mRNA abundances of PDX-1 and MafA were not altered by
siRNA-induced down-regulation of HMGA1 (Figure 4C).
Taken together, these data confirm and extend previous obser-
vations and provide strong evidence that HMGA1 is required for
full transactivation of the INS gene in beta cells.
EFFECTS OF HMGA1 ON GLUCOSE-INDUCED INS GENE EXPRESSION
AND INSULIN SECRETION
High glucose levels not only trigger a rapid secretion of insulin
stored in the beta-cell but also stimulate the synthesis of new
insulin molecules by inducing INS gene transcription. As reported
previously, one of the mechanisms whereby glucose stimulates INS
gene transcription in pancreatic beta cells is via activation and
nuclear translocation of the transcription factor PDX-1 (25, 47),
in addition to the up-regulation of MafA transcription (48). In
the light of the data presented above, indicating the cooperative
interactions between HMGA1, PDX-1, and MafA, we investigated
whether HMGA1 plays a role in glucose-induced insulin tran-
scription. To this end, we first carried out ChIP experiments
in INS-1 cells at basal (3 mM) and stimulatory (15 mM) glu-
cose concentrations. Results showed that binding of HMGA1 to
the A3/A4 region of the INS gene promoter was low in INS-1
cells incubated in low glucose condition, while this binding was
significantly increased under high glucose conditions (Figure 5A).
These findings demonstrate that binding of HMGA1 to the INS
promoter is stimulated by high glucose and indicate that HMGA1
could mediate the INS transactivation ability of high glucose. To
further support this conclusion, HMGA1 siRNA-treated INS-1
cells were used to test the effects of glucose on insulin release
into the culture medium. As shown in Figure 5B, a significant
increase in insulin secretion was obtained when the medium
glucose content was increased from 3 to 15 mM. No further
increase in insulin secretion was observed by transfection with
HMGA1 expression vector, most probably due to the endogenous
HMGA1 present in INS-1 cells. However, pretreatment of INS-
1 cells with HMGA1 siRNA resulted in a significant reduction
in glucose-induced insulin secretion into the incubation medium
(Figure 5B), confirming the central importance of HMGA1 in this
scenario. Taken together, these results provide new insights into
the molecular mechanisms regulating INS gene expression and
emphasize the role of HMGA1 as an essential molecule necessary
for proper beta-cell insulin secretion.
DISCUSSION
Functional defects in the pancreatic beta-cell result in type 2 dia-
betes mellitus, a metabolic disorder in which, for various reasons,
beta-cell insulin secretion may be profoundly affected at the mul-
tiple stages of the natural history of the disease. At the initial
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FIGURE 3 | Functional significance of HMGA1, PDX-1, and MafA for
INS gene transcription. HEK-293 cells were cotransfected with 1µg of
human (phINS-Luc) (A) or mouse (pmINSII-Luc) (B) Luc reporter
plasmids, in the absence or presence of effector vectors for HMGA1,
PDX-1, and MafA (0.5µg each), either alone or in double or triple
combinations. Data represent the means±SE for three separate
experiments; values are expressed as factors by which Luc activity
increased as compared with the level of Luc activity obtained in
transfections with reporter vector alone (slashed bar), which is assigned
an arbitrary value of 1. Open bar, mock (no DNA); black bar, pGL3-basic
(vector without an insert). *p<0.05; **p<0.01; ***p<0.001 versus
control (slashed bar).
stage, peripheral insulin resistance increases demands of insulin
secretion to stabilize blood sugar, which requires increased insulin
transcription and translation (49). Yet sustained high glucose and
insulin secretion eventually induce stress responses in beta cells
to attenuate insulin production and secretion. Supporting the
complexity and the importance of insulin production and secre-
tion, genome-wide association studies have shown that most of
the multiple susceptibility genes that facilitate diabetes develop-
ment are involved in controlling beta-cell mass and function (1,
2). Thus, understanding factors that regulate insulin transcription
and translation is critical to prevent or delay the development of
type 2 diabetes.
By binding to AT-rich regions in the minor groove of DNA,
HMGA1 contributes importantly to the transcriptional activation
of many mammalian genes. By itself, HMGA1 has no intrinsic
transcriptional activity; rather, it binds DNA to modulate its con-
formation so that other transcription factors can be recruited
and assembled at the transcription initiation site to regulate tran-
scription (34–37). These findings suggest that HMGA1 acts as a
general nuclear factor to regulate gene expression. Indeed, pro-
moters of genes that are expressed in a tissue-specific fashion are
often regulated by the combination of tissue-specific and ubiqui-
tous nuclear proteins, where the ubiquitous factor can support
and facilitate the action of tissue-specific transcription factors
(36, 50). As a part of an investigation into the genetic basis of
insulin resistance syndromes and diabetes, we previously reported
that loss of HMGA1 expression considerably decreased beta-cell
insulin expression and severely reduced insulin secretion, caus-
ing a phenotype with hypoinsulinemia and glucose intolerance
(38). Interestingly, pancreatic islets from Hmga1-knockout mice
were nearly 80% smaller compared with wild-type islets, indicat-
ing that decreased insulin secretion in this mutant mouse model
was dependent, at least in part, on reduced beta-cell mass, and
suggesting that HMGA1 may play a direct role in pancreatic islet
development and insulin production.
In this study, we provide direct evidence that HMGA1 is
required for proper transcription of the INS gene in culture cells.
We show that functional integrity of HMGA1 was necessary for
full transactivation of the INS promoter by PDX-1 and MafA in
cells that do not normally produce insulin. In contrast, repression
of endogenous HMGA1 protein function adversely affected both
PDX-1- and MafA-induced transactivation of the INS gene in
insulin-producing cells. These findings demonstrate that HMGA1
plays significant roles in the transcriptional activities of these
nuclear factors in the context of the INS gene. Underscoring the
importance of this biochemical activity, our ChIP-qRT-PCR-based
analysis showed that glucose upregulates HMGA1’s activity to the
endogenous INS chromosomal locus. It is likely also that after
a glucose challenge a deficit in HMGA1 may dampen INS gene
transcriptional rate, thereby reducing insulin production.
Functional cooperation between HMGA1, PDX-1, and MafA
in the transactivation of the INS promoter could be mediated by
HMGA1-induced changes in DNA structure, thereby triggering
a chain of molecular events that enhances the affinity of PDX-1
and MafA for their target DNA sequence and perhaps for other
DNA-binding proteins that bind in the immediate vicinity, thus
promoting the formation of an active transcription complex to
which coactivators are recruited. While the biological relevance of
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FIGURE 4 | Suppression of INS promoter and mRNA by siRNA to
HMGA1. INS-1 (A) and HeLa (B) cells were incubated without or with
siRNA targeting HMGA1 (100 pmol) and transfected thereafter with 1µg
of mouse (pmINSII-Luc) or human (phINS-Luc) Luc reporter plasmid,
respectively, either in the absence or presence of effector vectors (0.5µg
each) for HMGA1, PDX-1, and MafA. Values are expressed relative to the
Luc activity obtained in transfections with the Luc reporter plasmid alone
(slashed bar) that is assigned an arbitrary value of 1. Results are the
means±SE of triplicates from three independent transfections. *p<0.05
versus control (slashed bar). (C) INS-1 cells were transfected with siRNA
against HMGA1 or a non-targeting control siRNA, and mRNA levels for
HMGA1, Insulin, PDX-1, and MafA were measured by quantitative RT-PCR
(qRT-PCR). Results are the mean±SEM of at least three separate
transfections, each in triplicate. *p<0.05 versus the relative control.
Western blots (WB) of HMGA1, either before or after HMGA1 siRNA
treatment, are shown in the autoradiograms and are from four
independent experiments. Densitometric slot blot analysis, using the
ImageJ software program, is shown. Numbers on the peaks are the size
of the corresponding slot as a percentage of the total size of the two slots
in each condition.
these findings with regard to type 1 and type 2 diabetes remains
to be clarified, it is tempting to hypothesize that a putative defect
in HMGA1, by adversely affecting binding of PDX-1 and MafA
to the INS gene, under either basal or glucose-stimulated condi-
tions, may impair INS gene transcription, leading to decreased
insulin synthesis and secretion. Consistent with the high sequence
homology of the human and mouse INS genes (7), our data on
in vitro INS gene transactivation demonstrate a striking similarity
between the two species. This is particularly noteworthy in the light
of several observations in the literature, indicating that substantial
differences exist in pancreatic islet morphogenesis and function
between humans and mice (38, 51, 52). Thus, caution is required
when generalizing these results, as well as additional confirmation
in future studies.
In conclusion, our data in the present work consistently sug-
gest that HMGA1 may act as a glucose sensor that facilitates
activation of the INS gene and insulin release. In addition, they fur-
ther support the notion that HMGA1 is an architectural element
www.frontiersin.org January 2015 | Volume 5 | Article 237 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arcidiacono et al. HMGA1 and insulin gene regulation
FIGURE 5 | Functional significance of HMGA1 for glucose-induced INS
gene expression and insulin secretion. (A) ChIP of the rat Ins promoter
gene in INS-1 cells treated with either basal (3 mM) or stimulatory (15 mM)
glucose concentrations, using an anti-HMGA1 specific antibody (Ab). A
representative assay is shown, together with qRT-PCR of ChIP-ed samples.
p<0.05 versus control (white bar). (B) Insulin secretion from HMGA1
siRNA-treated INS-1 cells. Results are the mean±SEM for three independent
experiments conducted in triplicate. p<0.05 versus control (white bar). A
representative WB of HMGA1 is shown in the autoradiogram, together with
densitometric slot blot analysis in each condition.
tightly linked to glucose metabolism and metabolic disorders (38,
44, 53–60). Future studies on the interplays among HMGA1,
PDX-1, and MafA might be useful in understanding the mole-
cular basis of clinical phenotypes in certain clinical conditions
where insulin secretion becomes compromised (i.e., diabetes mel-
litus and other categories of glucose intolerance). Understanding
these mechanisms should augment our capacity to identify novel
therapeutic targets for the prevention and treatment of these
diseases.
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